BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $406,625 | -2.4% | 23,641 | -6.0% | 0.01% | -7.1% |
| Q1 2023 | $416,771 | +117.6% | 25,137 | 0.0% | 0.01% | +100.0% |
| Q4 2022 | $191,544 | -23.4% | 25,137 | 0.0% | 0.01% | -36.4% |
| Q3 2022 | $250,000 | +9.6% | 25,137 | +0.2% | 0.01% | +10.0% |
| Q2 2022 | $228,000 | +9.1% | 25,096 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $209,000 | -21.7% | 25,096 | +340.1% | 0.01% | -20.0% |
| Q3 2021 | $267,000 | – | 5,702 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |